149 related articles for article (PubMed ID: 37953495)
1. Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.
Patel M; Partovi O; Karrento K; Garacchi Z; Balasubramanian G; Venkatesan T
Neurogastroenterol Motil; 2024 Jan; 36(1):e14705. PubMed ID: 37953495
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
4. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic Testing in Patients with Autism Spectrum Disorder Evaluated in a Precision Medicine Clinic.
Goodson R; Wagner J; Sandritter T; Staggs VS; Soden S; Nadler C
J Dev Behav Pediatr; 2023 Oct-Nov 01; 44(8):e505-e510. PubMed ID: 37807195
[TBL] [Abstract][Full Text] [Related]
6. Frequencies of
Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
[TBL] [Abstract][Full Text] [Related]
7. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
[TBL] [Abstract][Full Text] [Related]
8. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.
Ryu S; Park S; Lee JH; Kim YR; Na HS; Lim HS; Choi HY; Hwang IY; Lee JG; Park ZW; Oh WY; Kim JM; Choi SE
Clin Transl Sci; 2017 Mar; 10(2):93-101. PubMed ID: 28296334
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
[TBL] [Abstract][Full Text] [Related]
10. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
11. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Solomon HV; Cates KW; Li KJ
Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
[TBL] [Abstract][Full Text] [Related]
12. Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response.
Scherf-Clavel M; Weber H; Wurst C; Stonawski S; Hommers L; Unterecker S; Wolf C; Domschke K; Rost N; Brückl T; Lucae S; Uhr M; Binder EB; Menke A; Deckert J
Pharmacopsychiatry; 2022 Sep; 55(5):246-254. PubMed ID: 35839823
[TBL] [Abstract][Full Text] [Related]
13. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
[TBL] [Abstract][Full Text] [Related]
14. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System.
Hellwig LD; Turner C; Olsen C; Libbus J; Markos B; Koehlmoos T; Haigney M; De Castro M; Saunders D
Mil Med; 2024 Jan; 189(1-2):e198-e204. PubMed ID: 37436924
[TBL] [Abstract][Full Text] [Related]
15. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
Smith RL; Molden E; Bernard JP
Br J Clin Pharmacol; 2023 Jul; 89(7):2246-2253. PubMed ID: 36851891
[TBL] [Abstract][Full Text] [Related]
17. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
18. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
